Antibiotic-free Microbial Expression and Genetic Systems

A world leading health company is seeking novel antibiotic-free microbial expression systems for production of a wide range of biologics including recombinant proteins, peptides, antigens, Fc-fusion proteins, and monoclonal antibodies. Additionally, the team is looking for partners and/or technologies to support removal of AMR genes from bacterial genomes through genetic modification.

Approaches of Interest:

• Bacterial or cell-based expression systems that are cost-effective, produce a high biologic yield and have scalable manufacturing capability are of interest
• Escherichia coli systems are of highest interest, however Gram-positive systems from manufacturable strains will be considered
• Host strains will ideally be low or free from endotoxins and systems that have control of contamination and genetic drift are preferred
• Technologies must be robust (e.g., replication, genetic stability, inducible protein expression, ease of purification) and without requirements for rare or expensive components
• Contamination and genetic drift will ideally be controlled

Out of Scope:

• Plasmid selection relying on toxin/anti-toxin maintenance
• CHO and other mammalian cell lines (NS0, Sp2/0, BHK, Murine C127, HeLa, HEK293, Sf9, MCF-7)

Developmental Stages of Interest:

• Ready-to-use expression systems are of priority; however systems with evidence of inducible expression will be considered 

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information. Please be aware that regional restrictions apply to this campaign – submissions must originate from regions that are free, low risk, or not affected with foreign animal diseases. Submissions from US and western Europe are prioritised, but a full list of preferred regions is found here.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets and research collaborations for further development of the expression system. An exclusive license for commercial use is preferred.